Karyopharm Therapeutics Inc (KPTI)
1.15
+0.02
(+1.32%)
USD |
NASDAQ |
May 17, 16:00
1.15
0.00 (0.00%)
After-Hours: 20:00
Karyopharm Therapeutics Revenue (Annual): 146.03M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 146.03M |
| December 31, 2022 | 157.07M |
| December 31, 2021 | 209.82M |
| December 31, 2020 | 108.08M |
| December 31, 2019 | 40.89M |
| December 31, 2018 | 30.34M |
| December 31, 2017 | 1.605M |
| Date | Value |
|---|---|
| December 31, 2016 | 0.154M |
| December 31, 2015 | 0.25M |
| December 31, 2014 | 0.229M |
| December 31, 2013 | 0.387M |
| December 31, 2012 | 0.634M |
| December 31, 2011 | 0.152M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
40.89M
Minimum
2019
209.82M
Maximum
2021
132.38M
Average
146.03M
Median
2023
Revenue (Annual) Benchmarks
| Geron Corp | 0.237M |
| Arbutus Biopharma Corp | 18.14M |
| Verastem Inc | -- |
| Actinium Pharmaceuticals Inc | 0.081M |
| Chimerix Inc | 0.324M |